Browse PRR5L

Summary
SymbolPRR5L
Nameproline rich 5 like
Aliases FLJ14213; PROTOR-2; protein observed with Rictor-2; PROTOR2; Proline-rich protein 5-like
Chromosomal Location11p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF08539 HbrB-like
Function

Associates with the mTORC2 complex that regulates cellular processes including survival and organization of the cytoskeleton (PubMed:17461779). Regulates the activity of the mTORC2 complex in a substrate-specific manner preventing for instance the specific phosphorylation of PKCs and thereby controlling cell migration (PubMed:22609986). Plays a role in the stimulation of ZFP36-mediated mRNA decay of several ZFP36-associated mRNAs, such as TNF-alpha and GM-CSF, in response to stress (PubMed:21964062). Required for ZFP36 localization to cytoplasmic stress granule (SG) and P-body (PB) in response to stress (PubMed:21964062).

> Gene Ontology
 
Biological Process GO:0001667 ameboidal-type cell migration
GO:0001933 negative regulation of protein phosphorylation
GO:0006401 RNA catabolic process
GO:0006402 mRNA catabolic process
GO:0006979 response to oxidative stress
GO:0009894 regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0010761 fibroblast migration
GO:0010762 regulation of fibroblast migration
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling
GO:0019439 aromatic compound catabolic process
GO:0031329 regulation of cellular catabolic process
GO:0031331 positive regulation of cellular catabolic process
GO:0031929 TOR signaling
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0033157 regulation of intracellular protein transport
GO:0034599 cellular response to oxidative stress
GO:0034655 nucleobase-containing compound catabolic process
GO:0038203 TORC2 signaling
GO:0042326 negative regulation of phosphorylation
GO:0044270 cellular nitrogen compound catabolic process
GO:0046700 heterocycle catabolic process
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0051222 positive regulation of protein transport
GO:0061013 regulation of mRNA catabolic process
GO:0061014 positive regulation of mRNA catabolic process
GO:0090316 positive regulation of intracellular protein transport
GO:1901361 organic cyclic compound catabolic process
GO:1903311 regulation of mRNA metabolic process
GO:1903313 positive regulation of mRNA metabolic process
GO:1903829 positive regulation of cellular protein localization
GO:1904951 positive regulation of establishment of protein localization
Molecular Function GO:0031625 ubiquitin protein ligase binding
GO:0044389 ubiquitin-like protein ligase binding
Cellular Component GO:0031932 TORC2 complex
GO:0038201 TOR complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolPRR5L
Nameproline rich 5 like
Aliases FLJ14213; PROTOR-2; protein observed with Rictor-2; PROTOR2; Proline-rich protein 5-like
Chromosomal Location11p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PRR5L and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPRR5L
Nameproline rich 5 like
Aliases FLJ14213; PROTOR-2; protein observed with Rictor-2; PROTOR2; Proline-rich protein 5-like
Chromosomal Location11p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PRR5L in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPRR5L
Nameproline rich 5 like
Aliases FLJ14213; PROTOR-2; protein observed with Rictor-2; PROTOR2; Proline-rich protein 5-like
Chromosomal Location11p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PRR5L in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7490.0062
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.980.184
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5810.32
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2830.519
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1340.918
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4820.793
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0240.949
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2550.791
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3030.767
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.770.51
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.160.507
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4860.00142
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PRR5L in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.6013.60.279
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPRR5L
Nameproline rich 5 like
Aliases FLJ14213; PROTOR-2; protein observed with Rictor-2; PROTOR2; Proline-rich protein 5-like
Chromosomal Location11p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PRR5L. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPRR5L
Nameproline rich 5 like
Aliases FLJ14213; PROTOR-2; protein observed with Rictor-2; PROTOR2; Proline-rich protein 5-like
Chromosomal Location11p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PRR5L. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PRR5L.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPRR5L
Nameproline rich 5 like
Aliases FLJ14213; PROTOR-2; protein observed with Rictor-2; PROTOR2; Proline-rich protein 5-like
Chromosomal Location11p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PRR5L. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPRR5L
Nameproline rich 5 like
Aliases FLJ14213; PROTOR-2; protein observed with Rictor-2; PROTOR2; Proline-rich protein 5-like
Chromosomal Location11p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PRR5L expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPRR5L
Nameproline rich 5 like
Aliases FLJ14213; PROTOR-2; protein observed with Rictor-2; PROTOR2; Proline-rich protein 5-like
Chromosomal Location11p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PRR5L and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPRR5L
Nameproline rich 5 like
Aliases FLJ14213; PROTOR-2; protein observed with Rictor-2; PROTOR2; Proline-rich protein 5-like
Chromosomal Location11p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PRR5L collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.